Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arovella Therapeutics Limited ( (AU:ALA) ) has shared an announcement.
Arovella Therapeutics Limited has notified the ASX that Andrew Nash ceased to be a director of the company effective 4 May 2026. The final director’s interest notice confirms that Nash held no relevant interests in Arovella securities or related contracts, indicating no equity or contractual ties with the company at the time of his departure.
The disclosure fulfills Arovella’s obligations under ASX listing rule 3.19A.3 and section 205G of the Corporations Act, maintaining transparency around board changes. For shareholders and governance observers, the update signals a clean exit with no outstanding security holdings or related-party interests linked to the departing director.
More about Arovella Therapeutics Limited
Arovella Therapeutics Limited is an Australia-listed biotechnology company operating in the therapeutic sector. While this specific filing does not detail its product pipeline, the company is subject to ASX corporate governance and disclosure rules, reflecting its status as a publicly traded life sciences entity focused on regulated capital markets.
Average Trading Volume: 909,114
Technical Sentiment Signal: Sell
Current Market Cap: A$84.61M
Learn more about ALA stock on TipRanks’ Stock Analysis page.